Results of treatment of advanced stage Hodgkin lymphoma with standard or escalated BEACOPP + RT: the German Hodgkin Study Group (GHSG) trial HD9.
| . | COPP/ABVD + RT (A) . | BEACOPP std esc + RT (B) . | BEACOPP + RT (C) . | p(A vs C) . |
|---|---|---|---|---|
| Abbreviations: std, standard; esc, escalated; CR, complete response; FFTF, freedom from treatment failure; IPFP, International Prognostic Factors Project score; NS, not significant; AML/myelodys, acute myelogenous leukemia or myelodysplasia; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and procarbazine; RT, radiation therapy. | ||||
| N | 260 | 469 | 466 | |
| CR % | 84 | 88 | 96 | |
| 5 y FFTF % | 67 | 75 | 85 | < 0.001 |
| 5 y OS % | 79 | 84 | 90 | 0.004 |
| 5 y OS % | ||||
| IPFP 0,1 | 91 | 91 | 95 | NS |
| IPFP 2,3 | 81 | 90 | 90 | NS |
| IPFP 4–7 | 57 | 85 | 77 | < 0.0099 |
| AML/myelodys (n,%) | 1 (0.3) | 5 (1.0) | 11 (2.3) | |
| . | COPP/ABVD + RT (A) . | BEACOPP std esc + RT (B) . | BEACOPP + RT (C) . | p(A vs C) . |
|---|---|---|---|---|
| Abbreviations: std, standard; esc, escalated; CR, complete response; FFTF, freedom from treatment failure; IPFP, International Prognostic Factors Project score; NS, not significant; AML/myelodys, acute myelogenous leukemia or myelodysplasia; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone and procarbazine; RT, radiation therapy. | ||||
| N | 260 | 469 | 466 | |
| CR % | 84 | 88 | 96 | |
| 5 y FFTF % | 67 | 75 | 85 | < 0.001 |
| 5 y OS % | 79 | 84 | 90 | 0.004 |
| 5 y OS % | ||||
| IPFP 0,1 | 91 | 91 | 95 | NS |
| IPFP 2,3 | 81 | 90 | 90 | NS |
| IPFP 4–7 | 57 | 85 | 77 | < 0.0099 |
| AML/myelodys (n,%) | 1 (0.3) | 5 (1.0) | 11 (2.3) | |